Volume 66, Issue 2, Pages (February 2017)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 62, Issue 6, Pages (June 2015)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 66, Issue 5, Pages (May 2017)
Inflammasomes in liver diseases
Volume 58, Issue 6, Pages (June 2013)
Volume 65, Issue 4, Pages (October 2016)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Volume 51, Issue 3, Pages (September 2009)
Update on primary sclerosing cholangitis
Y. Huang, X.-F. Tian, X.-G. Fan, C.-Y. Fu, C. Zhu 
Volume 21, Issue 13, Pages (December 2017)
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 14, Issue 6, Pages (February 2016)
Volume 122, Issue 1, Pages (January 2002)
Volume 17, Issue 2, Pages (February 2015)
Volume 64, Issue 5, Pages (May 2016)
Volume 53, Issue 5, Pages (November 2010)
IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection  Hannah K. Bayes, Neil D. Ritchie, Christopher Ward,
Volume 20, Issue 2, Pages (July 2017)
Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?
Microbiota studies in the bile duct strongly suggest a role for Helicobacter pylori in extrahepatic cholangiocarcinoma  F. Avilés-Jiménez, A. Guitron,
Volume 84, Issue 2, Pages (August 2013)
Volume 44, Issue 6, Pages (June 2006)
Volume 44, Issue 6, Pages (June 2006)
Volume 58, Issue 6, Pages (June 2013)
Volume 44, Issue 4, Pages (April 2006)
Volume 44, Issue 5, Pages (May 2006)
Volume 66, Issue 1, Pages (January 2017)
Volume 62, Issue 5, Pages (May 2015)
Volume 60, Issue 6, Pages (June 2014)
Volume 21, Issue 13, Pages (December 2017)
Volume 42, Issue 2, Pages (February 2005)
What is the long-term outcome of the liver allograft?
The Absence of a Microbiota Enhances TSLP Expression in Mice with Defective Skin Barrier but Does Not Affect the Severity of their Allergic Inflammation 
Volume 4, Issue 4, Pages (October 2008)
Cross-Differentiation from the CD8 Lineage to CD4 T Cells in the Gut-Associated Microenvironment with a Nonessential Role of Microbiota  Jen Bon Lui,
Volume 64, Issue 5, Pages (May 2016)
Hepatic hepcidin expression is decreased in cirrhosis and HCC
Volume 65, Issue 4, Pages (October 2016)
Volume 53, Issue 5, Pages (November 2010)
Liver transplantation for primary sclerosing cholangitis
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 53, Issue 2, Pages (August 2010)
Volume 65, Issue 2, Pages (August 2016)
Volume 60, Issue 4, Pages (April 2014)
Volume 69, Issue 5, Pages (November 2018)
Volume 42, Issue 6, Pages (June 2005)
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 44, Issue 2, Pages (February 2006)
Volume 64, Issue 6, Pages (June 2016)
Volume 63, Issue 1, Pages (July 2015)
Serum HBV pgRNA as a clinical marker for cccDNA activity
The use of hemospray in portal hypertensive bleeding; a case series
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Volume 62, Issue 3, Pages (March 2015)
Early-Life Antibiotic Exposure Causes Intestinal Dysbiosis and Exacerbates Skin and Lung Pathology in Experimental Systemic Sclerosis  Heena Mehta, Philippe-Olivier.
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Volume 71, Issue 1, Pages (July 2019)
Volume 41, Issue 1, Pages (July 2014)
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti– Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC  Yueping.
by Peter J. Turnbaugh, Vanessa K. Ridaura, Jeremiah J
Defective NOD2 peptidoglycan sensing promotes diet‐induced inflammation, dysbiosis, and insulin resistance Unweighted UniFrac principal coordinates analysis.
Defective NOD2 peptidoglycan sensing promotes diet‐induced inflammation, dysbiosis, and insulin resistance APrincipal coordinates analysis (PCoA) performed.
Comparison of distal gut microbiota composition between Egyptian and U
Presentation transcript:

Volume 66, Issue 2, Pages 382-389 (February 2017) The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation  Elisabeth Schrumpf, Martin Kummen, Laura Valestrand, Thomas U. Greiner, Kristian Holm, Velmurugesan Arulampalam, Henrik M. Reims, John Baines, Fredrik Bäckhed, Tom H. Karlsen, Richard S. Blumberg, Johannes R. Hov, Espen Melum  Journal of Hepatology  Volume 66, Issue 2, Pages 382-389 (February 2017) DOI: 10.1016/j.jhep.2016.09.020 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 NOD.c3c4 mice have a distinct global bacterial composition compared with NOD control mice. Principal coordinate plot based on unweighted UniFrac distances illustrating separation of the NOD (n=4–5) and NOD.c3c4 mice (n=5) in cecal content and mucosa (A) before (p<0.01) and (B) after rederivation into another conventional animal facility (p<0.02). (C) Intra-individual diversity measured by Shannon Diversity Index in cecal content of NOD (n=4–5) and NOD.c3c4 mice (n=5) was similar. Data in (A) and (B) compared using the anosim function in QIIME. Data in (C) are presented as mean±SEM, unpaired Student’s t test used for comparison. Journal of Hepatology 2017 66, 382-389DOI: (10.1016/j.jhep.2016.09.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Germ free (GF) NOD.c3c4 mice have lower liver weight and less distended common bile ducts than conventionally raised (CONV-R) NOD.c3c4 mice. (A) Total body weight and (B) liver weight as percentage of body weight of CONV-R and GF NOD.c3c4 mice at 9 (n=9 in each group) and 18weeks (w) of age (n=11 in each group). (C) Liver weight as percentage of body weight of CONV-R and GF NOD mice at 9 (GF: n=9, CONV-R: n=5) and 18 w of age (GF: n=4, CONV-R: n=5). (D) Log-transformed common bile duct dilatation (CBDD) of CONV-R and GF NOD.c3c4 mice at 9 (n=9 in each group) and 18 w of age (n=11 in each group). Data are presented as mean±SEM, unpaired Student’s t test was used for comparison. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001. Journal of Hepatology 2017 66, 382-389DOI: (10.1016/j.jhep.2016.09.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Germ free (GF) NOD.c3c4 mice have reduced inflammatory portal infiltrates compared with conventionally raised (CONV-R) NOD.c3c4 mice at 18weeks of age. (A) H&E (40×) and Sirius Red stained sections (40×, 10×) illustrating portal inflammation, bile infarcts and fibrosis. (B) Liver pathology in GF (n=11) and CONV-R (n=11) NOD.c3c4 mice scored on parameters portal inflammation, bile infarcts, fibrosis and dilatation of intrahepatic bile ducts (IHBD). Data are presented as mean±SEM, unpaired Student’s t test was used for comparison. ∗p<0.05. Journal of Hepatology 2017 66, 382-389DOI: (10.1016/j.jhep.2016.09.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Germ free (GF) NOD.c3c4 mice have less CD3, Ly6G and Mac-2 positive cells around their bile ducts compared with conventionally raised (CONV-R) NOD.c3c4 mice. (A) CD3, Ly6G and Mac-2 positive cells around bile ducts (indicated by arrows) in 18weeks old CONV-R (n=11) and GF (n=11) NOD.c3c4 mice (40×). (B) Mean CD3/Ly6G/Mac-2 positive cell count from six different areas with bile ducts of CONV-R and GF NOD.c3c4 mice. CD3, Ly6G and Mac-2 are makers of T cells, neutrophils and macrophages, respectively. Data are presented as mean±SEM, for CD3+ count unpaired Student’s t test was used, for Ly6G+ and Mac-2+ count Mann-Whitney U test was used for comparison due to a non-normal data distribution. ∗p<0.05, ∗∗∗p<0.001. Journal of Hepatology 2017 66, 382-389DOI: (10.1016/j.jhep.2016.09.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Antibiotic treated (AB) NOD.c3c4 mice have lower liver weight and less biliary infarcts compared with NOD.c3c4 mice receiving normal drinking water (control). (A) Liver weight as percentage of body weight of AB NOD.c3c4 (n=19) and control NOD.c3c4 (n=19) mice. AB NOD.c3c4 mice received treatment for 4weeks from weaning. (B) Log-transformed common bile duct dilatation (CBDD) and (C) alanine transaminase (ALT) levels measured in serum of AB and control NOD.c3c4 mice. (D) Liver pathology scored on parameters portal inflammation, bile infarcts, fibrosis and dilatation of intrahepatic bile ducts (IHBD). The data represents results from two pooled, independent experiments. Data are presented as mean±SEM, unpaired Student’s t test was used for comparison. ∗p<0.05, ∗∗∗p<0.001. Journal of Hepatology 2017 66, 382-389DOI: (10.1016/j.jhep.2016.09.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2017 66, 382-389DOI: (10. 1016/j. jhep. 2016. 09 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions